General Information of Drug (ID: DMWV8C6)

Drug Name
CA-4948 Drug Info
Synonyms
RWIMETUXCNDSLE-UHFFFAOYSA-N; SCHEMBL16896371; GTPL10152; CA4948; AU4948; AU-4948; example 1 [WO2015104688A1]; HY-109585; CS-0032273; 6'-Amino-N-[2-(morpholin-4-yl)-[1,3]oxazolo[4,5-b]pyridin-6-yl]-[2,3'-bipyridine]-6-carboxamide; 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Cross-matching ID
PubChem CID
118224238
TTD Drug ID
DMWV8C6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-5718 DMRKU0L Rheumatoid arthritis FA20 Phase 2 [2]
Zabedosertib DMEZGWP Atopic dermatitis EA80 Phase 2 [3]
BAY1834845 DM8V62T Psoriasis vulgaris EA90 Phase 1 [4]
AZD6793 DM5GRZV Inflammation 1A00-CA43.1 Phase 1 [5]
SAR444656 DMIF2OL Atopic dermatitis EA80 Phase 1 [6]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z N. A. N. A. Patented [7]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 N. A. N. A. Patented [7]
Indazoletriazolephenyl derivative 1 DMHJDU6 N. A. N. A. Patented [7]
Indazoletriazolephenyl derivative 2 DMWZLK6 N. A. N. A. Patented [7]
Indazole amide derivative 2 DMRPT5O N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Renal carcinoma antigen NY-REN-64 (IRAK-4) TTKFVXR IRAK4_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
3 Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of AstraZeneca
6 Clinical pipeline report, company report or official report of Sanofi
7 Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.